Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine.

J Acquir Immune Defic Syndr. 1994 Nov;7(11):1141-8. Unique Identifier : AIDSLINE MED/95017545
Alder J; Hutch T; Meulbroek JA; Clement JC; Department of Anti-infective Microbiology, Abbott Laboratories,; Abbott Park, Illinois 60064-3500.

Abstract: The efficacy of clarithromycin combined with either pyrimethamine or minocycline for treatment of experimental Toxoplasma gondii infection was investigated. Mice were infected intraperitoneally with 2 x 10(3) to 2 x 10(4) T. gondii strain RH or TS4 tachyzoites. Mortality was recorded for 35 days postinfection. Latency was evaluated by inoculation of brain homogenates from surviving mice into naive untreated mice. The combination of clarithromycin and pyrimethamine therapy caused a significantly greater reduction in mortality than did either drug alone. Similar synergy was observed between clarithromycin and minocycline. A 100% cure rate of active and latent infection was achieved in mice treated with the clarithromycin based combinations. Clarithromycin in combination with either pyrimethamine or minocycline produced efficacy comparable to combined therapy of pyrimethamine with sulfamethoxazole. The in vitro potency of clarithromycin, pyrimethamine, or minocycline against T. gondii on a mouse macrophage monolayer was not predictive of the in vivo efficacy in mice. Clarithromycin combined with minocycline or pyrimethamine could allow greater flexability for treatment of patients predisposed to the toxicity associated with standard pyrimethamine-sulfonamide or pyrimethamine-nonsulfonamide therapy. This therapy could be especially useful since clarithromycin-based therapy provides safe and effective treatment against Mycobacterium avium complex infections associated with AIDS patients.

Keywords: Animal AIDS-Related Opportunistic Infections/*DRUG THERAPY Clarithromycin/PHARMACOLOGY/PHARMACOKINETICS/*THERAPEUTIC USE Disease Models, Animal Dose-Response Relationship, Drug Drug Synergism Drug Therapy, Combination Female Mice Minocycline/PHARMACOLOGY/PHARMACOKINETICS/*THERAPEUTIC USE Pyrimethamine/PHARMACOLOGY/PHARMACOKINETICS/*THERAPEUTIC USE Sulfamethoxazole/THERAPEUTIC USE Toxoplasma/DRUG EFFECTS Toxoplasmosis, Animal/*DRUG THERAPY JOURNAL ARTICLE
950130
M9510468

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .